Cymbalta Approved; Lilly Antidepressant Will Be Available By Late August
This article was originally published in The Pink Sheet Daily
Executive Summary
Cymbalta (duloxetine) clears FDA for major depressive disorder after a lengthy review. It will be priced comparably to other antidepressants, including Wyeth's Effexor XR (venlafaxine), the other marketed selective serotonin/norepinephrine reuptake inhibitor.